NO20011745D0 - Tetrahydrobenzazepin-derivater anvendelige som modulatorer av dopamin D3-reseptorer (antipsykotiske midler) - Google Patents
Tetrahydrobenzazepin-derivater anvendelige som modulatorer av dopamin D3-reseptorer (antipsykotiske midler)Info
- Publication number
- NO20011745D0 NO20011745D0 NO20011745A NO20011745A NO20011745D0 NO 20011745 D0 NO20011745 D0 NO 20011745D0 NO 20011745 A NO20011745 A NO 20011745A NO 20011745 A NO20011745 A NO 20011745A NO 20011745 D0 NO20011745 D0 NO 20011745D0
- Authority
- NO
- Norway
- Prior art keywords
- dopamine
- modulators
- receptors
- derivatives useful
- antipsychotic agents
- Prior art date
Links
- MZBVNYACSSGXID-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-1-benzazepine Chemical class N1CCCCC2=CC=CC=C21 MZBVNYACSSGXID-UHFFFAOYSA-N 0.000 title 1
- 102000004073 Dopamine D3 Receptors Human genes 0.000 title 1
- 108090000525 Dopamine D3 Receptors Proteins 0.000 title 1
- 239000000164 antipsychotic agent Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Anesthesiology (AREA)
- Otolaryngology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9821976.9A GB9821976D0 (en) | 1998-10-08 | 1998-10-08 | Compounds |
| GBGB9824340.5A GB9824340D0 (en) | 1998-11-06 | 1998-11-06 | Compounds |
| GBGB9910711.2A GB9910711D0 (en) | 1999-05-07 | 1999-05-07 | Compounds |
| GBGB9918032.5A GB9918032D0 (en) | 1999-07-30 | 1999-07-30 | Compounds |
| PCT/EP1999/007763 WO2000021951A1 (en) | 1998-10-08 | 1999-10-06 | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20011745D0 true NO20011745D0 (no) | 2001-04-06 |
| NO20011745L NO20011745L (no) | 2001-06-06 |
Family
ID=27451837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20011745A NO20011745L (no) | 1998-10-08 | 2001-04-06 | Forbindelser |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6605607B1 (no) |
| EP (1) | EP1119563B1 (no) |
| JP (1) | JP2002527433A (no) |
| KR (1) | KR20010085898A (no) |
| CN (1) | CN1329609A (no) |
| AP (1) | AP2001002114A0 (no) |
| AR (1) | AR023681A1 (no) |
| AT (1) | ATE316969T1 (no) |
| AU (1) | AU761018B2 (no) |
| BG (1) | BG105467A (no) |
| BR (1) | BR9914370A (no) |
| CA (1) | CA2346689A1 (no) |
| CO (1) | CO5140073A1 (no) |
| CZ (1) | CZ20011270A3 (no) |
| DE (1) | DE69929704T2 (no) |
| EA (1) | EA200100428A1 (no) |
| ES (1) | ES2255311T3 (no) |
| HK (1) | HK1038745A1 (no) |
| HU (1) | HUP0104280A3 (no) |
| ID (1) | ID28385A (no) |
| IL (1) | IL142388A0 (no) |
| MA (1) | MA26696A1 (no) |
| NO (1) | NO20011745L (no) |
| NZ (1) | NZ511018A (no) |
| OA (1) | OA11663A (no) |
| PE (1) | PE20001088A1 (no) |
| PL (1) | PL347237A1 (no) |
| SK (1) | SK4782001A3 (no) |
| TR (1) | TR200101025T2 (no) |
| WO (1) | WO2000021951A1 (no) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9810876D0 (en) | 1998-05-20 | 1998-07-22 | Smithkline Beecham Plc | Compounds |
| AU761018B2 (en) | 1998-10-08 | 2003-05-29 | Smithkline Beecham Plc | Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents) |
| US7229986B2 (en) | 2000-05-16 | 2007-06-12 | Takeda Pharmaceutical Company Ltd. | Melanin-concentrating hormone antagonist |
| KR20030045187A (ko) * | 2000-11-14 | 2003-06-09 | 스미스클라인비이참피이엘시이 | 도파민 ｄ₃수용체 조절제 (정신병 치료제)로서 유용한테트라히드로벤즈아제핀 유도체 |
| WO2002051232A2 (en) | 2000-12-27 | 2002-07-04 | Actelion Pharmaceuticals Ltd. | Novel benzazepines and related heterocyclic derivatives |
| HU227543B1 (en) * | 2001-09-28 | 2011-08-29 | Richter Gedeon Nyrt | N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them |
| WO2003062205A1 (en) * | 2001-12-21 | 2003-07-31 | Smithkline Beecham P.L.C. | 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment of cns disorders |
| US20050085461A1 (en) * | 2002-02-13 | 2005-04-21 | Cooper David G. | Benzenesulfonamide derivatives |
| DE60325025D1 (de) | 2002-02-15 | 2009-01-15 | Glaxo Group Ltd | Modulatoren des vanilloidrezeptors |
| GB0224083D0 (en) * | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| CA2509413C (en) | 2002-12-20 | 2012-05-01 | Glaxo Group Limited | Benzazepine derivatives for the treatment of neurological disorders |
| US6992096B2 (en) | 2003-04-11 | 2006-01-31 | Ptc Therapeutics, Inc. | 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| JP4982184B2 (ja) | 2003-12-18 | 2012-07-25 | アボット ゲーエムベーハー ウント カンパニー カーゲー | テトラヒドロベンズアゼピンおよびドーパミンｄ３レセプターの調節におけるこれらの使用 |
| US20050137186A1 (en) | 2003-12-18 | 2005-06-23 | Abbott Gmbh & Co. Kg. | Tetrahydrobenzazepines and their use |
| GB0330043D0 (en) | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them |
| GB0330042D0 (en) | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them |
| EP1725238A4 (en) * | 2004-03-17 | 2009-04-01 | Glaxo Group Ltd | M 3 MUSCARINACETYLCHOLINE RECEPTOR ANTAGONISTS |
| WO2005094834A1 (en) * | 2004-03-17 | 2005-10-13 | Glaxo Group Limited | Muscarinic acetylcholine receptor antagonists |
| WO2005094835A1 (en) * | 2004-03-17 | 2005-10-13 | Glaxo Group Limited | M3 muscarinic acetylcholine receptor antagonists |
| JP2009511530A (ja) * | 2005-10-13 | 2009-03-19 | モルフォケム アクチェンゲゼルシャフト フュア コンビナトリシェ ヘミー | 抗菌活性を有する５−キノリン誘導体 |
| KR102280530B1 (ko) * | 2013-12-13 | 2021-07-21 | 피에르 파브르 메디카먼트 | 자폐증 스펙트럼 장애의 치료에 사용되는 도파민 ｄ3 수용체 길항제로서의 크로모네 유도체 |
| US9873677B2 (en) | 2014-03-06 | 2018-01-23 | Ptc Therapeutics, Inc. | Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid |
| MX2018005361A (es) | 2015-10-30 | 2018-06-07 | Ptc Therapeutics Inc | Metodos para tratar epilepsia. |
| US10870660B2 (en) | 2016-07-28 | 2020-12-22 | Shionogi & Co., Ltd. | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect |
| US11014927B2 (en) | 2017-03-20 | 2021-05-25 | Forma Therapeutics, Inc. | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators |
| CN111433201B (zh) * | 2017-12-21 | 2022-05-27 | 江苏恒瑞医药股份有限公司 | 苯并氮杂䓬衍生物、其制备方法及其在医药上的应用 |
| CA3089498A1 (en) * | 2018-01-26 | 2019-08-01 | Shionogi & Co., Ltd. | Condensed ring compounds having dopamine d3 receptor antagonistic effect |
| CN110498768A (zh) * | 2018-05-17 | 2019-11-26 | 上海中泽医药科技有限公司 | 庚嗪类化合物及其在制备抗精神分裂症药物中的应用 |
| ES2989438T3 (es) | 2018-09-19 | 2024-11-26 | Novo Nordisk Healthcare Ag | Activación de la piruvato cinasa R |
| US12053458B2 (en) | 2018-09-19 | 2024-08-06 | Novo Nordisk Health Care Ag | Treating sickle cell disease with a pyruvate kinase R activating compound |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
| EP4031132A4 (en) | 2019-09-19 | 2023-09-13 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA792785B (en) | 1978-07-07 | 1980-08-27 | Smithkline Corp | Mercapto substituted-2,3,4,5-tetrahydro-1h-3-benzazepines |
| US4220778A (en) | 1978-10-30 | 1980-09-02 | G. D. Searle & Co. | 8-Aryl-1,2,3,4-tetrahydroisoquinoline and derivatives thereof |
| IL63918A0 (en) | 1980-10-17 | 1981-12-31 | Pennwalt Corp | N-(amino(or hydroxy)phenethyl)-1,2,3,4-tetrahydroisoquinolines,their preparation and pharmaceutical compositions containing them |
| ZA816903B (en) | 1980-10-17 | 1983-02-23 | Pennwalt Corp | N-(amino(or hydroxy)-1,2,3,4,-tetrahydroisoquinolines, precursors thereof, and methods of preparation |
| FR2618149B1 (fr) | 1987-07-16 | 1989-09-22 | Synthelabo | Derives de n-aminoalkyl n-phenyl arylamides, leur preparation et leur application en therapeutique |
| IL89156A (en) | 1988-07-12 | 1993-05-13 | Synthelabo | Derivatives of 2-((4-piperidinyl) methyl)- 1,2,3,4- tetrahydroisoquinoline, their preparation and their application in therapeutics |
| US5217977A (en) | 1989-02-28 | 1993-06-08 | Imperial Chemical Industries Plc | Heterocyclic cycloalkanes |
| US5047406A (en) | 1989-12-06 | 1991-09-10 | Warner-Lambert Co. | Substituted cyclohexanols as central nervous system agents |
| US5633376A (en) | 1990-12-28 | 1997-05-27 | Neurogen Corporation | Certain aminomethyl phenylimidazole derivatives; and 4-aryl substituted piperazinyl and piperidinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype ligands |
| US5681956A (en) | 1990-12-28 | 1997-10-28 | Neurogen Corporation | 4-aryl substituted piperazinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands |
| DK0569380T3 (da) | 1991-01-11 | 1997-12-22 | Glaxo Lab Sa | Acridinderivater |
| US5466691A (en) | 1991-08-09 | 1995-11-14 | Yoshitomi Pharmaceutical Industries, Ltd. | Thiophene compound |
| US5532240A (en) | 1991-12-26 | 1996-07-02 | Yoshitomi Pharmaceutical Industries, Ltd. | Condensed thiophene compound and pharmaceutical use thereof |
| CA2104371A1 (en) | 1991-12-26 | 1993-06-27 | Tohru Nakao | Condensed thiophene compound and pharmaceutical use thereof |
| GB9206757D0 (en) | 1992-03-27 | 1992-05-13 | Ferring Bv | Novel peptide receptor ligands |
| JP2718830B2 (ja) | 1992-07-10 | 1998-02-25 | ラボラトワール、グラクソ、ソシエテ、アノニム | アニリド誘導体 |
| JPH07509705A (ja) | 1992-08-06 | 1995-10-26 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | ドーパミンｄ３レセプター拮抗薬用５−（２−オキシフェニル）−ピロール誘導体 |
| US5294621A (en) | 1992-10-07 | 1994-03-15 | Ortho Pharmaceutical Corporation | Thieno tetrahydropyridines useful as class III antiarrhythmic agents |
| GB9305644D0 (en) | 1993-03-18 | 1993-05-05 | Merck Sharp & Dohme | Therapeutic agents |
| GB9307400D0 (en) | 1993-04-08 | 1993-06-02 | Smithkline Beecham Plc | Compounds |
| FR2706895A1 (en) | 1993-06-22 | 1994-12-30 | Synthelabo | Tetrahydroisoquinoline derivatives, their preparation and their application in therapeutics |
| JP2959615B2 (ja) | 1993-06-24 | 1999-10-06 | 吉富製薬株式会社 | 縮合型チオフェン化合物およびその医薬用途 |
| EP0705259B1 (en) | 1993-06-25 | 1998-02-25 | Smithkline Beecham Plc | Phenyrrole derivatives and their use as dopamine d3 antagonists |
| GB9315801D0 (en) | 1993-07-30 | 1993-09-15 | Smithkline Beecham Plc | Compounds |
| GB9315800D0 (en) | 1993-07-30 | 1993-09-15 | Smithkline Beecham Plc | Compounds |
| PL180081B1 (pl) | 1993-08-12 | 2000-12-29 | Astra Ab | Nowe pochodne amidyny i sposób ich wytwarzania PL PL PL PL PL PL PL |
| AU7665694A (en) | 1993-09-21 | 1995-04-10 | Yamanouchi Pharmaceutical Co., Ltd. | N-(3-pyrrolidinyl)benzamide derivative |
| GB9320855D0 (en) | 1993-10-09 | 1993-12-01 | Smithkline Beecham Plc | Compounds |
| US6756388B1 (en) | 1993-10-12 | 2004-06-29 | Pfizer Inc. | Benzothiophenes and related compounds as estrogen agonists |
| GB9325827D0 (en) | 1993-12-17 | 1994-02-23 | Smithkline Beecham Plc | Compounds |
| GB9402197D0 (en) | 1994-02-04 | 1994-03-30 | Smithkline Beecham Plc | Compounds |
| GB9402807D0 (en) | 1994-02-14 | 1994-04-06 | Xenova Ltd | Pharmaceutical compounds |
| GB9403199D0 (en) | 1994-02-19 | 1994-04-13 | Smithkline Beecham Plc | Compounds |
| WO1995029891A1 (en) | 1994-04-28 | 1995-11-09 | Yamanouchi Pharmaceutical Co., Ltd. | N-(3-pyrrolidinyl)benzamide derivative |
| US5414010A (en) | 1994-05-10 | 1995-05-09 | Warner-Lambert Company | Dimeric benzimidazoles as central nervous system agents |
| DE4425146A1 (de) | 1994-07-15 | 1996-01-18 | Basf Ag | Verwendung heterocyclischer Verbindungen |
| DE4425143A1 (de) | 1994-07-15 | 1996-01-18 | Basf Ag | Substituierte Pyrimidinverbindungen und deren Verwendung |
| DE4425144A1 (de) | 1994-07-15 | 1996-01-18 | Basf Ag | Triazolverbindungen und deren Verwendung |
| DE4425145A1 (de) | 1994-07-15 | 1996-01-18 | Basf Ag | Verwendung von Thiazol- und Thiadiazolverbindungen |
| GB9418912D0 (en) | 1994-09-20 | 1994-11-09 | Fisons Corp | Pharmaceutically active compounds |
| PL319511A1 (en) | 1994-10-05 | 1997-08-18 | Glaxo Wellcome Inc | Parenteral pharmaceutic compositions containing gf120918a |
| US5478934A (en) | 1994-11-23 | 1995-12-26 | Yuan; Jun | Certain 1-substituted aminomethyl imidazole and pyrrole derivatives: novel dopamine receptor subtype specific ligands |
| AU4368996A (en) | 1994-11-23 | 1996-06-17 | Neurogen Corporation | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands |
| GB9426071D0 (en) | 1994-12-23 | 1995-02-22 | Xenova Ltd | Pharmaceutical compounds |
| GB9426090D0 (en) | 1994-12-23 | 1995-02-22 | Xenova Ltd | Pharmaceutical compounds |
| GB9426224D0 (en) | 1994-12-23 | 1995-02-22 | Xenova Ltd | Pharmaceutical compounds |
| US5891877A (en) | 1995-02-14 | 1999-04-06 | Xenova Limited | Pharmaceutical compounds |
| JP3332929B2 (ja) | 1995-02-15 | 2002-10-07 | ニューロゲン コーポレイション | ある種の架橋４−フェニル−２−アミノメチルイミダゾール：新しいドパミン受容体サブタイプ特異的リガンド |
| AU5147196A (en) | 1995-03-27 | 1996-10-16 | Smithkline Beecham Plc | Bicyclic amine derivatives and their use as anti-psychotic a gents |
| GB9512129D0 (en) | 1995-06-15 | 1995-08-16 | Smithkline Beecham Plc | Compounds |
| AU6859096A (en) | 1995-09-22 | 1997-04-09 | Warner-Lambert Company | Substituted cyclohexylamines as central nervous system agents |
| FR2741074B1 (fr) | 1995-11-09 | 1997-12-19 | Adir | Nouveaux composes tetracycliques de la 1,4-oxazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| DE19600934A1 (de) | 1996-01-12 | 1997-07-17 | Basf Ag | Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung |
| AU1597197A (en) | 1996-02-01 | 1997-08-22 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Thienoquinolines |
| WO1997029079A1 (en) | 1996-02-06 | 1997-08-14 | Japan Tobacco Inc. | Novel compounds and pharmaceutical use thereof |
| JPH09291034A (ja) | 1996-02-27 | 1997-11-11 | Yoshitomi Pharmaceut Ind Ltd | 縮合ピリジン化合物およびその医薬としての用途 |
| US5710274A (en) | 1996-02-28 | 1998-01-20 | Neurogen Corporation | N-aminoalkyldibenzofurancarboxamides; new dopamine receptor subtype specific ligands |
| US5763609A (en) | 1996-03-21 | 1998-06-09 | Neurogen Corporation | Certain pyrrolo pyridine-3-carboxamides; a new class of gaba brain receptor ligands |
| US5703237A (en) | 1996-04-18 | 1997-12-30 | Neurogen Corporation | N-Aminoalkyl-2-anthraquinonecarboxamides; new dopamine receptor subtype specific ligands |
| US5688950A (en) | 1996-04-23 | 1997-11-18 | Neurogen Corporation | Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands |
| CA2253927A1 (en) * | 1996-05-11 | 1997-11-20 | Smithkline Beecham P.L.C. | Tetrahydroisoquinoline derivatives as modulators of dopamine d3 receptors |
| GB9612153D0 (en) | 1996-06-11 | 1996-08-14 | Smithkline Beecham Plc | Compounds |
| JP2000517301A (ja) * | 1996-08-14 | 2000-12-26 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | テトラヒドロイソキノリン誘導体およびそれらの薬理学的使用 |
| US6429212B1 (en) | 1996-08-16 | 2002-08-06 | Ishihara Sangyo Kaisha Ltd. | Medicinal composition |
| EP0944602A1 (en) | 1996-11-27 | 1999-09-29 | Pfizer Inc. | Apo b-secretion/mtp inhibitory amides |
| FR2761985B1 (fr) | 1997-04-10 | 1999-05-21 | Adir | Nouveaux composes amines du 6,7,8,9-tetrahydro-cyclopenta[a] naphtalene et du 2,3-dihydro-cyclopenta[e]indene, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| IL132169A0 (en) | 1997-04-28 | 2001-03-19 | Univ British Columbia | Method and composition for modulating amyloidosis |
| GB9708694D0 (en) | 1997-04-30 | 1997-06-18 | Smithkline Beecham Plc | Compounds |
| GB9708805D0 (en) | 1997-05-01 | 1997-06-25 | Smithkline Beecham Plc | Compounds |
| BR9809591A (pt) | 1997-05-03 | 2001-09-11 | Smithkline Beecham Plc | Derivados de tetraidoisoquinolina como moduladores de receptores de dopamina d3 |
| GB9709303D0 (en) | 1997-05-09 | 1997-06-25 | Smithkline Beecham Plc | Compounds |
| GB9710612D0 (en) | 1997-05-23 | 1997-07-16 | Glaxo Group Ltd | Synthesis of acridine derivatives |
| DE19728996A1 (de) | 1997-07-07 | 1999-01-14 | Basf Ag | Triazolverbindungen und deren Verwendung |
| GB9810876D0 (en) | 1998-05-20 | 1998-07-22 | Smithkline Beecham Plc | Compounds |
| AU761018B2 (en) | 1998-10-08 | 2003-05-29 | Smithkline Beecham Plc | Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents) |
| GB9821977D0 (en) | 1998-10-08 | 1998-12-02 | Smithkline Beecham Plc | Compounds |
| TWI274750B (en) | 1999-01-12 | 2007-03-01 | Abbott Gmbh & Co Kg | Triazole compounds showing high affinity to dopamine D3 receptor and pharmaceutical composition comprising the same |
-
1999
- 1999-10-06 AU AU10381/00A patent/AU761018B2/en not_active Ceased
- 1999-10-06 AP APAP/P/2001/002114A patent/AP2001002114A0/en unknown
- 1999-10-06 KR KR1020017004442A patent/KR20010085898A/ko not_active Withdrawn
- 1999-10-06 CO CO99063348A patent/CO5140073A1/es unknown
- 1999-10-06 OA OA1200100090A patent/OA11663A/en unknown
- 1999-10-06 ID IDW20010785A patent/ID28385A/id unknown
- 1999-10-06 ES ES99953833T patent/ES2255311T3/es not_active Expired - Lifetime
- 1999-10-06 CN CN99814062A patent/CN1329609A/zh active Pending
- 1999-10-06 CZ CZ20011270A patent/CZ20011270A3/cs unknown
- 1999-10-06 AT AT99953833T patent/ATE316969T1/de not_active IP Right Cessation
- 1999-10-06 PL PL99347237A patent/PL347237A1/xx not_active Application Discontinuation
- 1999-10-06 HU HU0104280A patent/HUP0104280A3/hu unknown
- 1999-10-06 SK SK478-2001A patent/SK4782001A3/sk unknown
- 1999-10-06 TR TR2001/01025T patent/TR200101025T2/xx unknown
- 1999-10-06 EP EP99953833A patent/EP1119563B1/en not_active Expired - Lifetime
- 1999-10-06 NZ NZ511018A patent/NZ511018A/en unknown
- 1999-10-06 BR BR9914370-4A patent/BR9914370A/pt not_active IP Right Cessation
- 1999-10-06 PE PE1999001015A patent/PE20001088A1/es not_active Application Discontinuation
- 1999-10-06 JP JP2000575857A patent/JP2002527433A/ja not_active Withdrawn
- 1999-10-06 DE DE69929704T patent/DE69929704T2/de not_active Expired - Fee Related
- 1999-10-06 WO PCT/EP1999/007763 patent/WO2000021951A1/en not_active Ceased
- 1999-10-06 EA EA200100428A patent/EA200100428A1/ru unknown
- 1999-10-06 CA CA002346689A patent/CA2346689A1/en not_active Abandoned
- 1999-10-06 MA MA25809A patent/MA26696A1/fr unknown
- 1999-10-06 AR ARP990105055A patent/AR023681A1/es not_active Application Discontinuation
- 1999-10-06 HK HK02100150.4A patent/HK1038745A1/zh unknown
- 1999-10-06 US US09/806,902 patent/US6605607B1/en not_active Expired - Fee Related
- 1999-10-06 IL IL14238899A patent/IL142388A0/xx unknown
-
2001
- 2001-04-06 NO NO20011745A patent/NO20011745L/no not_active Application Discontinuation
- 2001-04-24 BG BG105467A patent/BG105467A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR023681A1 (es) | 2002-09-04 |
| AP2001002114A0 (en) | 2001-06-30 |
| DE69929704D1 (de) | 2006-04-13 |
| WO2000021951A1 (en) | 2000-04-20 |
| IL142388A0 (en) | 2002-03-10 |
| CA2346689A1 (en) | 2000-04-20 |
| HUP0104280A2 (hu) | 2002-03-28 |
| OA11663A (en) | 2004-12-08 |
| TR200101025T2 (tr) | 2001-09-21 |
| NZ511018A (en) | 2003-09-26 |
| HK1038745A1 (zh) | 2002-03-28 |
| CZ20011270A3 (cs) | 2001-09-12 |
| AU1038100A (en) | 2000-05-01 |
| PE20001088A1 (es) | 2000-12-02 |
| EP1119563A1 (en) | 2001-08-01 |
| HUP0104280A3 (en) | 2002-07-29 |
| KR20010085898A (ko) | 2001-09-07 |
| BG105467A (en) | 2001-11-30 |
| EP1119563B1 (en) | 2006-02-01 |
| ES2255311T3 (es) | 2006-06-16 |
| CN1329609A (zh) | 2002-01-02 |
| MA26696A1 (fr) | 2004-12-20 |
| ID28385A (id) | 2001-05-17 |
| PL347237A1 (en) | 2002-03-25 |
| BR9914370A (pt) | 2001-11-27 |
| JP2002527433A (ja) | 2002-08-27 |
| US6605607B1 (en) | 2003-08-12 |
| SK4782001A3 (en) | 2001-11-06 |
| AU761018B2 (en) | 2003-05-29 |
| NO20011745L (no) | 2001-06-06 |
| ATE316969T1 (de) | 2006-02-15 |
| DE69929704T2 (de) | 2006-07-20 |
| EA200100428A1 (ru) | 2001-10-22 |
| CO5140073A1 (es) | 2002-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20011745D0 (no) | Tetrahydrobenzazepin-derivater anvendelige som modulatorer av dopamin D3-reseptorer (antipsykotiske midler) | |
| NO20032161D0 (no) | Tetrahydrobenzazepinderivater for anvendelse som modulatorer av dopamin D3-reseptorer (antipsykotiske midler) | |
| NO995338D0 (no) | Tetrahydroisokinolinderivater som modulatorer for dopamin-D3-reseptorer | |
| NO985242D0 (no) | Tetrahydroisokinolin-derivater som modulatorer for dopamin D3-reseptorer | |
| NO20022105D0 (no) | Positive modulatorer av nikotinreseptoragonister | |
| DK1102762T3 (da) | 2-substituerede-1-piperidylbenzimidazolforbindelser som ORL1-receptoragonister | |
| DK1001934T3 (da) | Indolforbindelser som COX-2-inhibitorer | |
| NO20013559L (no) | Aromatiske heterocykliske forbindelser som anti- inflammatoriske midler | |
| NO20005084D0 (no) | Heterosykliske glysyl <beta>-alanin derivater som vitronektinantagonister | |
| PT1049689E (pt) | Compostos de 4-(2-ceto-1-benzimidazolinil)piperidina como agonistas do receptor orl1 | |
| NO20015855L (no) | Ny anvendelse av forbindelser som antibakterielle midler | |
| NO20021251D0 (no) | Tienoisoksazolyl- og tienylpyrrazolyl-fenoksysubstituerte propylderivater anvendelige som D4antagonister | |
| DK0696194T3 (da) | Anvendelse af indolderivater som 5HT1-antagonister | |
| NO994106L (no) | Oksazolidiner som 5-HT2A-antagonister | |
| DK1464641T3 (da) | 4-phenylpiperazinyl-, -piperidinyl- og -tetrahydropyridylderivater som dopamin-D4-antagonister | |
| EP1434786A4 (en) | ANDROSTAN-17-BETA-CARBOXAMIDE AS MODULATORS OF THE ANDROGEN RECEPTOR | |
| NO993812L (no) | (4-piperidinyl)-1H-2benzopyranderivater som er anvendbare som antipsykotiske midler | |
| AU4262799A (en) | Tetraisoquinololine derivatives as modulators of dopamine d3 receptors | |
| DE69903627D1 (de) | Tetrahydroisochinolinderivate als modulatoren von dopamin d3 rezeptoren | |
| NO20012939D0 (no) | Substituerte heterocykliske acyltripeptider for anvendelse som trombin-receptor-modulatorer | |
| DE60023020D1 (de) | Positive modulatoren von nicotinrezeptor-agonisten | |
| HK1061388A (en) | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) | |
| NO20015378L (no) | Cyklokarbamatderivater som progesteronreseptormodulatorer | |
| DK1207159T3 (da) | Heteroaromatiske derivater som dopamin-D4-receptorantagonister | |
| NO20021249L (no) | Tienoisoksazolfenoksyusubstituerte etyl- og propylderivater anvendbare som D4antagonister |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |